90 With DHL or EMS (by  CSH01.2C-NN-ENS-EN2-CCD-NN-S-NN-FW about Details warranty) XH #G113n Microcontrollers

  1. Home
  2. 90 With DHL or EMS (by  CSH01.2C-NN-ENS-EN2-CCD-NN-S-NN-FW about Details warranty) XH #G113n
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Details about   CSH01.2C-NN-ENS-EN2-CCD-NN-S-NN-FW (by EMS or DHL With 90 warranty) #G113n XH
Condition: Used: An item that has been used previously. The item may have some signs of cosmetic wear, but is fully Brand: Unbranded
Item must be returned within: 60 Days MPN: Does Not Apply
Refund will be given as: Money Back Restocking Fee: No
Return shipping will be paid by: Buyer All returns accepted: Returns Accepted
Compatible CPU Brand: AMD UPC: Does not apply

published on tue nov 09 2021

90 With DHL or EMS (by  CSH01.2C-NN-ENS-EN2-CCD-NN-S-NN-FW about Details warranty) XH #G113n Microcontrollers

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

90 With DHL or EMS (by  CSH01.2C-NN-ENS-EN2-CCD-NN-S-NN-FW about Details warranty) XH #G113n Microcontrollers

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.